ClinicaliQ Trial Snapshot
- Phase III Study of AK112 for NSCLC Patients — Active Not Recruiting • Phase III • Oncology • NCT06396065.
- AK112 plus chemotherapy improved outcomes in advanced lung cancer patients whose tumours had stopped responding to targeted therapy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi) Conditions: Non-Squamous Non-small Cell Lung Cancer Interventions: AK112 Injection, Placebo Injection Lead Sponsor: Summit Therapeutics Planned Enrollment: 420 participants